Emerging role of PPAR ligands in the management of diabetic nephropathy

Pharmacological Research

Volumn 60, Issue 3, 2009, Pages 170-173

  Balakumar, Pitchai ^a   Arora, Mandeep Kumar ^a   Singh, Manjeet ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Diabetic nephropathy; PPAR agonists; PPAR agonists; PPAR agonists

Indexed keywords

ALBUMIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BEZAFIBRATE; CIGLITAZONE; COLLAGEN TYPE 4; CREATININE; CYCLOOXYGENASE 2; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GELATINASE B; GEMFIBROZIL; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERSTITIAL COLLAGENASE; LIPID; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; TRANSFORMING GROWTH FACTOR BETA; TROGLITAZONE; UNCLASSIFIED DRUG; VASCULOTROPIN; YM 440;

ANTIOXIDANT ACTIVITY; APOPTOSIS; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG MECHANISM; GLOMERULUS FILTRATION RATE; HUMAN; HYPERGLYCEMIA; INHIBITION KINETICS; MORBIDITY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RENAL PROTECTION; REVIEW;

ANIMALS; DIABETIC NEPHROPATHIES; HUMANS; LIGANDS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; PROTEIN ISOFORMS;

EID: 67349188030     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2009.01.010     Document Type: Review

References (44)

1. Fowler M.J. Microvascular and macrovascular complications of diabetes. Clin Diab 26 (2008) 77-82
2. Mauer S.M. Structural-functional correlations of diabetic nephropathy. Kidney Int 45 (1994) 612-622
3. Balakumar P., Chakkarwar V.A., Krishan P., and Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy?. Biomed Pharmacother (2008) 10.1016/J.Bio.Pha.2008.08.008
4. Rodby R.A. Lewis. ACE inhibition in diabetic patients: economic implications. Eur J Pharmacoecon 10 (1996) 315-320
5. Hunsicker L.G. Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J Manag Care Pharm 10 (2004) S12-S17
6. Buse J.B. Glitazones and heart failure: critical appraisal for the clinicians. Circulation 108 (2003) e57
7. Nagai T., Tomizawa T., and Mori M. Effect of bezafibrate or pravastatin on serum lipid level and albuminuria in NIDDM patients. J Atheroscler Thromb 7 (2000) 91-96
8. Pitrosch F., Herbrig K., Kinder B., Passauer J., Fisher S., and Gross P. Rosiglitazone improves glomerular hyperfilteration, renal endothelial dysfunction and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54 (2005) 2206-2211
9. Balakumar P., Rose M., and Singh M. PPAR ligands: are they potential agent for cardiovascular disorders?. Pharmacology 80 (2007) 1-10
10. Braissant O., Foufelle F., Scotto C., Dauca M., and Whalli M. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPARalpha -beta and -gamma in the adult rats. Endocrinology 137 (1996) 354-366
11. Ricote M., Li A.C., Willson T.M., Kelly C.J., and Glass C.K. The peroxisome proliferator-activated receptor-gamma is negative regulator of macrophages activation. Nature 391 (1998) 79-82
12. Stael B., Koenig W., Habib A., Merval R., Lebret M., Torra I.P., et al. Activation of human aortic smooth muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 393 (1998) 790-793
13. Marx N., Sukhova G.K., Collin T., Libby P., and Plutzky J. PPAR alpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99 (1999) 3125-3131
14. Ferre P. The biology of peroxisome proliferator-activated receptor: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (2004) 543-550
15. Balakumar P., Rose M., Ganti S.S., Krishan P., and Singh M. PPAR dual agonist: are they opening pandora's box?. Pharmacol Res 56 (2007) 91-98
16. Rose M., Balakumar P., and Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overloaded-induced hypertrophy in rats. Pharmacology 80 (2007) 1772-1784
17. Ravid M., Neumann L., and Lishner M. Plasma lipids and progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int 47 (1995) 907-910
18. Smulders Y.M., Van eeden A.E., Stehouwer C.D.A., Weijers R.N.M., Slaats E.H., and Silberbusch J. Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus?. Eur J Clin Invest 27 (1997) 997-1002
19. Bonnet F., and Cooper M.E. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diab Metab 26 (2000) 254-264
20. Rosario R.F., and Sharma P. Lipids and diabetic nephropathy. Curr Diab Rep 6 (2006) 455-462
21. Munter P., Coresh J., Smith J.C., Eckfeldt J., and Klag M.J. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 58 (2000) 293-301
22. Scheuer H., Gwinner W., Hohbach J., Grone E.F., Brandes R.P., Malle E., et al. Oxidant stress in hyperlipidemia-induced renal damage. Am J Physiol Ren Physiol 278 (2000) F63-F74
23. Trevisan R., Dodesini A.R., and Lepore G. Lipids and renal disease. J Am Soc Nephrol 17 (2006) S145-S147
24. Sun L., Halaihel N., Zhang W., Rogers T., and Levi M. Role of sterol regulatory element-binding protein-1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277 (2002) 18919-18927
25. db/db mice with type 2 diabetes. Diabetes 54 (2005) 2328-2335
26. Park C.W., Kim H.W., Ko S.H., Chung H.W., Lim S.W., Yang C.W., et al. Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptorα. Diabetes 55 (2006) 885-893
27. Balakumar P., Chakkarwar V.A., and Singh M. Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Mol Cell Biochem 320 (2009) 149-162
28. Park C.W., Zhang Y., Zhang X., Wu J., Chen L., Cha D.R., et al. PPARα agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 69 (2006) 1511-1517
29. Chen Y.J., and Quilley J. Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase expression and enhanced renal prostaglandin release. J Phamacol Exp Ther 324 (2008) 658-663
30. Calkin A.C., Giunti S., Dahm K.A.J., Allen T.J., Cooper M.E., and Thomas M.C. PPAR-α and -γ agonists attenuate diabetic kidney disease in the apolipoprotein E knockout mouse. Nephrol Dial Transplant 21 (2006) 2399-2405
31. Asano T., Wakisaka M., Yoshinari M., Iino K., Sonari K., Iwase M., et al. Peroxisome proliferator-activated receptor gamma (PPAR gamma) expresses in rat mesangial cells and PPAR gamma agonist modulare its differentiation. Biochem Biophysiol Acta 1497 (2000) 148-154
32. Nicholas S.B., Kawano Y., Wakino S., Collin A.R., and Hsueh W.A. Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells. Hypertension 37 (2001) 722-727
33. Verma S., and Szmitko P.E. The vascular biology of peroxisome proliferator-activated receptors: modulation of atherosclerosis. Can J Cardiol 22 (2006) B12-B17
34. Zheng F., Fornoni A., Elliot S.J., Guan Y., Breyer M.D., Striker L.J., et al. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPAR-γ activation. Am J Physiol Ren Physiol 282 (2002) F639-F648
35. Zeng L., Huang S.M., Cai W.L., Fu P., and Zhou L. Effects of rosiglitazone on the expression of beta-1 integrin and ICAM-1 in high glucose-induced rat glomerular mesangial cells. Sichuan Da Xue Xue Bao Yi Xue Ban 37 (2006) 599-601 610
36. Zhang H., Saha J., Byun J., Schin M.L., Lorenz M., and Kennedy R.T. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolic abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Ren Physiol 295 (2008) F1071-F1081
37. Nakano R., Kurosaki E., Shimaya A., Kajikawa S., and Shibasaki M. YM 440 a novel hypoglycaemic agent, protects against nephropathy in zucker fatty rats via plasma triglyceride reduction. Eur J Pharmacol 549 (2006) 185-191
38. Sen U., Rodriguez W.E., Tyagi N., Kumar M., Kundu S., and Tyagi S.C. Ciglitazone, a PPARγ agonist ameliorates diabetic nephropathy, in part, through homocysteine clearance. Am J Physiol Endocrinol Metab 295 (2008) E1205-E1212
39. Okada T., Wada J., Hida K., Equchi J., Hashimoto I., Baba M., et al. Thiazolidinediones ameliorate diabetic nephropathy via cell cycle-dependent mechanisms. Diabetes 55 (2006) 1666-1677
40. Ohga S., Shikata K., Yozai K., Okada S., Ogawa D., Usui H., et al. Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Ren Physiol 292 (2007) F1141-F1150
41. Ko G.J., Kang Y.S., Han S.Y., Lee M.H., Sang H.K., and Han K.H. Pioglitazone attenuates diabetic nephropathy through an antiinflammatory mechanism in type 2 diabetic rats. Nephrol Dial Transplant 23 (2008) 2750-2760
42. Matsui T., Yamagishi S., Ueda S., Nakamura K., Imaizumi T., Takeuchi M., et al. Telmisartan, an angiotensin II type 1 receptor blocker, inhibits advance glycation end-products (AGE)-induced monocyte chemoattractant protein-1 expression in mesangial cells through downregulation of receptor for AGEs via peroxisome proliferator-activated receptor-gamma activation. J Int Med Res 35 (2007) 482-489
43. Yao Y., Zou R., Liu X., Jiang J., Huang Q., He Y., et al. Telmisartan but not valasartan inhibits TGF-beta-mediated accumulation of PPAR gamma. J Huazhong Univ Sci Technol Med Sci 28 (2008) 543-548
44. Cha D.R., Zang X., Zang Y., Wu J., Su D., Han J.Y., et al. Peroxisome proliferator-activated receptor α/γ dual agonist tesaglitazar attenuate diabetic nephropathy in db/db mice. Diabetes 56 (2007) 2036-2045